Hypnotic, antiepileptic and antiparkinsonian drugs

Июль 23, 2022

Главная
Медицина
Hypnotic, antiepileptic and antiparkinsonian drugs

Содержание

2. SEDATIVE-HYPNOTIC DRUGS I. Benzodiazepine Receptor Agonists 1. BZD compounds: Diazepam –Tab. 5 mg; amp. 0.5%-2 ml
3. II. Hypnotics with Narcotic Effect 1. Barbiturates: ■ Long-acting: 1 - 2 days Phenobarbital (Luminal) –
5. iI
6. iI
7. MECHANISM OF ACTION of BZDs Bind to the α-subunit of the GABAA Rs surrounding the Cl
8. Antispasticity Effect: - action on GABAA Rs in the Brain Stem Spinal Chord Sedative and Anticonvulsant
9. MECHANISM OF ACTION of Barbiturates Bind to the β-subunit of the GABAA Receptor surrounding the Cl
10. Rapid Eye Movement (REM) During sleep, the brain generates a rhythmic activity. Internal sleep cycles recur
12. PHENOBARBITAL (Luminal ) Tab. 0.005, 0.05 and 0.1 g Bind to β-subunit of the GABAA Rs
13. Pharmacological Effects of Barbiturates 1. Depression of the CNS 2. Respiratory Depression 3. Enzyme Induction: Barbiturates
14. Clinical Uses of Barbituretes: ⮟ 1. Anesthesia: Thiopental Sodium IV to induce general anesthesia. ⮟ 2.
15. Adverse Effects of Barbiturates: 1. Drowsiness, impaired concentration, mental and physical sluggishness 2. Drug hangover: a
16. Poisoning with Barbiturates I Stage (Falling Asleep): slurred speech, sustained Nystagmus, Somnolence; Apathy, Miosis, Bradycardia, Hypersalivation.
17. Treatment of Poisoning with Barbiturates Forced Alkaline Diuresis, Adequate Fluids, Acid-base Balance Correction Mannitol, Furosemide (Lasix)
18. VITAMINS: B1 6% 5 ml, B6 5% 6-8 ml, B12 600 μg C 5% 5-10 ml.
19. Drugs Used to Treat Epilepcy
20. Antiepileptic Drugs I. Delaying the recovery from inactivating Na+ channels: Carbamazepine (Finlepsin) Oxcarbazepine Diphenin (Phenytoin)
21. Carbamazepine - tab. 0.2 g, 0.4 g Mechanism of action: It blocks Na+ channels => Propagation
22. Diphenin (Phenytoin, Hydantoin ) - Tab 0.117 g; amp. 5%-5 ml Mechanism of action: ⮇ Influx
23. Teratogenic Effects of Diphenin Fetal Hydantoin Syndrome: Cleft Lip (hare lip) Cleft Palate Congenital Heart Disease
24. II. GABA-mimetics: 1. Stimulating GABA-ergic transmission: Sodium Oxybutyrate (Sodium oxybate) 2. Activating GABA Receptors: BARBITURATES, BENZODIAZEPINES
25. ● Valproate Sodium (Depakin ) Tab. 0.3 g; amp. 10% - 5 ml; Syrup 5%-120 ml
26. III. Inhibiting Excitatory Neurotransmitters and NMDA-receptors: Lamotrigine IV. Inhibitig Low threshold (T-current) Ca2+ channels in the
27. Lamotrigine - Tab. 0.05 and 0.1 g an Inhibitor of Exciting Amino Acids – Glutamate and
28. Classification of Epilepsy 1. PARTIAL: a. Simple Partial b. Complex Partial 2. GENERALIZED: a. Tonic-clonic (Grand
32. Antiparkinsonian Drugs I. Activating Dopaminergic Influences: 1. Precursors of Dopamine: Levodopa (Tab. 0.25 and 0.5 g)
33. II. Inhibiting Glutamatergic Influences: Amantadine (Midantane – tab. 0.1 g) III. Inhibiting Cholinergic Influences: Cyclodol (tab.
34. Levodopa ( L-DOPA, Dopar ) - a Laevorotatory Isomer of DOPA (Dihydroxy-Phenylalanine) – a precursor of
35. Adverse effect of Levodopa: Anorexia, Vomiting Cardiac Arrhythmias Orthostatic Hypotension Aggressive Behavior Seizures Hallucinations, Confusion, Delirium
36. Carbidopa and Benserazide - inhibitors of DOPA decarboxylase – do not penetrate the Blood-Brain barrier =>
37. Sinemet (Nakom) : Levodopa 100 mg + Carbidopa 25 mg Madopar : Levodopa 100 or 200
38. Bromocriptine, an ergotamine derivative, is a Dopamine Receptor Agonist. The actions are similar to those of
39. Selegiline (Deprenil) – MAO-B inhibitor Mechanism of Action: This is a selective, irreversible inhibitor of Monoamine
41. Скачать презентацию

Слайд 2

SEDATIVE-HYPNOTIC DRUGS
I. Benzodiazepine Receptor Agonists
1. BZD compounds:
Diazepam –Tab. 5 mg; amp.

0.5%-2 ml
Nitrazepam – Tab. 5 and 10 mg
Lorazepam – Tab. 1 and 2 mg, amp. 0. 2% - 1ml
Phenazepam – Tab. 0.5 and 1 mg
Alprazolam (Xanax) – Tab. 0.25 and 0.5 mg
Chlordiazepoxide
Nozepam (Oxazepam, Tazepam) – Tab. 10 mg
2. Agents of other chemical groups:
Zolpidem – Tab. 10 mg
Zopiclone – Tab. 7.5 mg

Слайд 3

II. Hypnotics with Narcotic Effect
1. Barbiturates:
■ Long-acting: 1 - 2

days
Phenobarbital (Luminal) – Tab. 0.005, 0.05 and 0.1 g
■ Short-acting: 3 - 8 hours
Amobarbital – Tab. 0.03, 0.05, 0.1 g; Vial 0.5 g
Secobarbital – Caps. 0.05 and 0.1 g; syringe 5% - 2 ml
Pentobarbital
■ Ultra-short acting: 20 min
Thiopental sodium (Aethaminalum-natrium, Nembutal)
2. Non-barbiturate hypnotics:
Chloral hydrate - powder

Слайд 4

Слайд 5

iI

Слайд 6

iI

Слайд 7

MECHANISM OF ACTION of BZDs
Bind to the α-subunit of the

GABAA Rs
surrounding the Cl ¯ channels
Designated as BZD Rs (omega-receptors)
? Affinity of GABA receptors
? Frequency of Cl ¯ channel opening
? Cl ¯ conductance => HYPERPOLARIZATION
INHIBITION of ACTION POTENTIAL formation and
further NEURONAL FIRING
BZDs ?turnover of 5-HT and NORADRENALINE

Слайд 8

Antispasticity Effect:
- action on GABAA Rs in the

Brain Stem
Spinal Chord
Sedative and Anticonvulsant effects:
- are localized to the Limbic System.
Seadtive-hypnotic Effect:
- is due to their actions on the omega-1 Rs
Impairment of Memory:
- action on the omega-2 Rs

Слайд 9

MECHANISM OF ACTION of Barbiturates
Bind to the β-subunit of the

GABAA Receptor surrounding
the Cl ¯ channels.
They facilitate the actions of GABA at multiple sites in the CNS and hyperpolarize the post-synaptic cell,
? Duration of the GABA-gated Chloride Channel openings.
At lower doses they enhance the action of GABA whereas
in larger doses they may also be GABA-mimetic,
directly activating Chloride Channels.
Barbiturates also inhibit the excitatory AMPA-glutamate receptors. They are less selective than BZDs, since they also depress
the actions of excitatory neurotransmitters (e.g., glutamic acid)

Слайд 10

Rapid Eye Movement (REM)
During sleep, the brain generates a rhythmic activity.
Internal

sleep cycles recur 4-5 times per night, each cycle
being interrupted by a Rapid Eye Movement sleep phase.
The REM stage is characterized by EEG activity similar to that
seen in the waking state, Rapid Eye Movements, Vivid Dreams,
and occasional twitches of individual muscle groups against
a background of generalized atonia of skeletal musculature.
The REM stage is entered after a non-REM cycle (NREM).
All hypnotics shorten the time spent in the REM stages !!
With repeated ingestion of a hypnotic for several successive days, the proportion of time spent in REM vs. non-REM sleep returns to normal despite continued drug intake.
Withdrawal of the hypnotic drug results in REM rebound, which tapers off over many days.
Since REM stages are associated with vivid dreaming, sleep with excessively long REM episodes is experienced as unrefreshing.
The attempt to discontinue use of hypnotics may result in the impression that refreshing sleep calls for a hypnotic, promoting
Hypnotic Drug Dependence.

Слайд 11

Слайд 12

PHENOBARBITAL (Luminal )
Tab. 0.005, 0.05 and 0.1 g
Bind to β-subunit of

the GABAA Rs
=> Facilitate the actions of GABA
DURATION of the GABA-gated
Cl ¯ channel openings
⮟is a potent inducer of the P-450 system, and it enhances the metabolism of other agents

Слайд 13

Pharmacological Effects of Barbiturates
1. Depression of the CNS
2.

Respiratory Depression
3. Enzyme Induction:
Barbiturates induce P-450 microsomal enzymes in the liver.

Слайд 14

Clinical Uses of Barbituretes:
⮟ 1. Anesthesia:
Thiopental Sodium IV to induce
general

anesthesia.
⮟ 2. Anticonvulsant:
Phenobarbital - in long-term management of Tonic-clonic Seizures
Status Epilepticus
Eclampsia.
⮟ 3. Insomnia.
⮟ 4. Preoperative sedation

Слайд 15

Adverse Effects of Barbiturates:
1. Drowsiness, impaired concentration,
mental and physical sluggishness
2.

Drug hangover: a feeling of tiredness
after the patient awakes
3. Barbiturates induce the P-450 system and
may ?the effect of drugs that
are metabolized by these hepatic enzymes

Слайд 16

Poisoning with Barbiturates
I Stage (Falling Asleep): slurred speech, sustained Nystagmus,

Somnolence; Apathy, Miosis,
Bradycardia, Hypersalivation.
II Stage (Superficial Coma): unconsciousness, Tachycardia, Muscle Hypotonia or Hypertonia,
Decrease or Increase of Reflexes,
Miosis. Rare and Superficial Breathing,
Weak Pulse, Cyanosis, Oliguria
III Stage (Deep Coma): Areflexia,
Absence of Reaction to Painful Stimulation.
IV Stage: (Post Comatose Period): Ptosis, Unsteady Gate,
Emotional Lability, Depression.

Слайд 17

Treatment of Poisoning with Barbiturates
Forced Alkaline Diuresis,
Adequate Fluids, Acid-base

Balance Correction
Mannitol, Furosemide (Lasix)
Sodium Bicarbonate 4% 500 ml IV
Intensive Infusion Therapy with
Polyglucin, Rheopolyglucin, Hemodes
Antidote Therapy:
Bemegrid 0.5% 5-10 ml IV or IM
Sulfacamphocaine
Coffeine-sodium bensoate
Ephedrine hydrochloride
Cordiamine

Слайд 18

VITAMINS:
B1 6% 5 ml,
B6 5% 6-8 ml,
B12 600 μg

C 5% 5-10 ml.
ATP 1% - 6 ml
Noradrenaline hydrotartrate 0.2% - 1 ml
combined with
Dopamine 4% - 5 ml
in Polyglucin (Macrodex) 400 ml IV infusion

Слайд 19

Drugs Used to Treat Epilepcy

Слайд 20

Antiepileptic Drugs
I. Delaying the recovery from inactivating Na+ channels:
Carbamazepine (Finlepsin)
Oxcarbazepine
Diphenin

(Phenytoin)

Слайд 21

Carbamazepine - tab. 0.2 g, 0.4 g
Mechanism of action: It blocks

Na+ channels =>
Propagation of abnormal impulses
Generation of repetitive action potentials
in the Epileptic Focus
Clinical Uses:
Partial Seizures (Simple and Complex) -
is the Drug of 1st Choice.
Tonic-Clonic Seizures
Trigeminal Neuralgia

Слайд 22

Diphenin (Phenytoin, Hydantoin )
- Tab 0.117 g; amp. 5%-5 ml
Mechanism of

action: ⮇ Influx of Na+ across
cell membranes in the motor cortex during
generation of nerve impulses
Adverse effects:
Gingival Hyperplasia, Nystagmus,
Ataxia.
Nystagmus - involuntary movement of the eye comprising a Smooth Drift followed by
a Flick Back

Слайд 23

Teratogenic Effects of Diphenin
Fetal Hydantoin Syndrome:
Cleft Lip (hare lip)
Cleft Palate

Congenital Heart Disease
Slowed Growth
Mental Deficiency

Слайд 24

II. GABA-mimetics:
1. Stimulating GABA-ergic transmission:
Sodium Oxybutyrate (Sodium oxybate)
2. Activating GABA Receptors:

BARBITURATES, BENZODIAZEPINES
3. Inhibiting GABA-transferase and ?GABA synthesis:
Sodium Valproate
4. Releasing GABA from neuronal endings:
Gabapentin
5. Inhibiting GABA transaminase:
Vigabatrine
6. Inhibiting GABA reuptake:
Tiagabine

Слайд 25

● Valproate Sodium (Depakin )
Tab. 0.3 g; amp. 10% -

5 ml;
Syrup 5%-120 ml
a Stimulator of GABA-ergic Processes
Mechanism of action:
● Inhibits GABA-transferase
● ?GABA synthesis =>
? Brain Levels of GABA
Propagation of abnormal electrical discharge
Adverse effects: ataxia, tremor, rash,
Hepatic toxicity,
Alopecia,
?Bleeding time

Слайд 26

III. Inhibiting Excitatory Neurotransmitters
and NMDA-receptors:
Lamotrigine
IV. Inhibitig Low threshold (T-current) Ca2+

channels
in the thalamic neurons:
Ethosuximide
Trimethine (Trimethadione)

Слайд 27

Lamotrigine - Tab. 0.05 and 0.1 g
an Inhibitor of

Exciting Amino Acids –
Glutamate and Asparginate
Mechanism of action:
inactivates voltage-sensitive Na+ Channels =>
inhibits the Release of Glutamate and Asparginate - Exciting Neurotransmitters
Clinical uses: partial and secondarily generalized seizures that are resistant to other drugs.
Adverse effects: nausea, headache, rash, diplopia, ataxia, hepatotoxicity, aggressiveness.

Слайд 28

Classification of Epilepsy
1. PARTIAL:
a. Simple Partial
b. Complex Partial
2. GENERALIZED:

a. Tonic-clonic (Grand mal)
b. Absence (Petit mal)
c. Myoclonic
d. Febrile Seizures
e. Status Epilepticus

Слайд 29

Слайд 30

Слайд 31

Слайд 32

Antiparkinsonian Drugs
I. Activating Dopaminergic Influences:
1. Precursors of Dopamine:
Levodopa (Tab. 0.25

and 0.5 g)
∙ Combined agents:
Sinemet (Nakom)
Madopar
2. D-receptor agonist:
Bromocriptine (tab. 2.5 mg)
Pergolide ( tab. 0.25 mg and 1 mg)
Cabergolin (tab. 0.5 mg)
3. MAO-B inhibitors:
Deprenil (Selegiline – tab. 5 mg)

Слайд 33

II. Inhibiting Glutamatergic Influences:
Amantadine (Midantane – tab. 0.1 g)
III. Inhibiting

Cholinergic Influences:
Cyclodol (tab. 1 mg, 2 mg and 5 mg)
Benztropine
Tropacine

Слайд 34

Levodopa ( L-DOPA, Dopar ) -
a Laevorotatory Isomer of

DOPA (Dihydroxy-Phenylalanine) –
a precursor of Dopamine
MA: Stimulates the D2 receptors in the basal ganglia
=> Improves modulation of Voluntary Nerve Impulses transmitted to the motor cortex
=> Relieves all major symptoms, esp.:
⮟ Akinesia (inability of voluntary movement)
⮟ Rigidity and Bradykinesia (Slowness of movement)
⮟ Akathisia (the inability to sit still because of uncontrollable movement)
⮟ Tremors
=> Improves Mood and Memory

Слайд 35

Adverse effect of Levodopa:
Anorexia, Vomiting
Cardiac Arrhythmias
Orthostatic Hypotension
Aggressive Behavior
Seizures
Hallucinations, Confusion, Delirium
Dyskinesia – Involuntary

Repetitive Movements
- in up to 80% of patients

Слайд 36

Carbidopa and Benserazide -
inhibitors of DOPA decarboxylase –
do not

penetrate the Blood-Brain barrier
=> less Levodopa is decarboxylated
in peripheral tissues
=> more Levodopa reaches the brain where
it is decarboxylated to DOPAMINE
=> much smaller doses
of Levodopa can be given.

Слайд 37

Sinemet (Nakom) :
Levodopa 100 mg + Carbidopa 25 mg
Madopar :

Levodopa 100 or 200 mg +
Carbidopa 25 mg or 50 mg respectively

Слайд 38

Bromocriptine, an ergotamine derivative,
is a Dopamine Receptor Agonist.
The actions are

similar to those of Levodopa,
except that
Hallucinations, Confusion, Delirium, Nausea, and Orthostatic Hypotension are more common,
whereas Dyskinesia is less prominent.
In psychiatric illness it causes the mental condition
to worsen.
In patients with Peripheral Vascular Disease
a worsening of the vasospasm occurs.
In patients with Peptic Ulcer, there is a worsening of the ulcer.

Слайд 39

Selegiline (Deprenil) – MAO-B inhibitor
Mechanism of Action: This is a selective,

irreversible inhibitor of Monoamine Oxidase type B,
thus decreasing the metabolism of Dopamine by
preventing inter-neuronal degradation.
Inhibition of this enzyme slows the breakdown of Dopamine
in the striatum.
Adverse reactions: can potentiate dyskinesia, mental and psychiatric adverse effects, and nausea due to levodopa dose.
If selegiline is administered in high doses, the selectivity of the drug is lost, and the patient is at risk for severe hypertension.
Selegiline increase the peak effect of L-DOPA and can worsen preexisting dyskinesia or psychiatric symptoms such as delusion and hallucination.
Contraindication: Selegiline should be avoided in patients with known falls, hallucinations, confusion and postural hypotension.

Hypnotic, antiepileptic and antiparkinsonian drugs

Содержание

SEDATIVE-HYPNOTIC DRUGSI. Benzodiazepine Receptor Agonists 1. BZD compounds: Diazepam –Tab. 5 mg; amp.

II. Hypnotics with Narcotic Effect1. Barbiturates: ■ Long-acting: 1 - 2

iI

iI

MECHANISM OF ACTION of BZDs Bind to the α-subunit of the

Antispasticity Effect: - action on GABAA Rs in the

MECHANISM OF ACTION of Barbiturates Bind to the β-subunit of the

Rapid Eye Movement (REM)During sleep, the brain generates a rhythmic activity.Internal

PHENOBARBITAL (Luminal ) Tab. 0.005, 0.05 and 0.1 gBind to β-subunit of

Pharmacological Effects of Barbiturates 1. Depression of the CNS 2.

Clinical Uses of Barbituretes:⮟ 1. Anesthesia: Thiopental Sodium IV to induce general

Adverse Effects of Barbiturates:1. Drowsiness, impaired concentration, mental and physical sluggishness2.

Poisoning with Barbiturates I Stage (Falling Asleep): slurred speech, sustained Nystagmus,

Treatment of Poisoning with Barbiturates Forced Alkaline Diuresis,Adequate Fluids, Acid-base

VITAMINS: B1 6% 5 ml, B6 5% 6-8 ml, B12 600 μg

Drugs Used to Treat Epilepcy

Antiepileptic Drugs I. Delaying the recovery from inactivating Na+ channels: Carbamazepine (Finlepsin) Oxcarbazepine Diphenin

Carbamazepine - tab. 0.2 g, 0.4 gMechanism of action: It blocks

Diphenin (Phenytoin, Hydantoin ) - Tab 0.117 g; amp. 5%-5 mlMechanism of

Teratogenic Effects of Diphenin Fetal Hydantoin Syndrome: Cleft Lip (hare lip) Cleft Palate

II. GABA-mimetics: 1. Stimulating GABA-ergic transmission: Sodium Oxybutyrate (Sodium oxybate) 2. Activating GABA Receptors:

● Valproate Sodium (Depakin ) Tab. 0.3 g; amp. 10% -

III. Inhibiting Excitatory Neurotransmitters and NMDA-receptors: LamotrigineIV. Inhibitig Low threshold (T-current) Ca2+

Lamotrigine - Tab. 0.05 and 0.1 g an Inhibitor of

Classification of Epilepsy1. PARTIAL: a. Simple Partial b. Complex Partial2. GENERALIZED:

Antiparkinsonian DrugsI. Activating Dopaminergic Influences: 1. Precursors of Dopamine: Levodopa (Tab. 0.25

II. Inhibiting Glutamatergic Influences: Amantadine (Midantane – tab. 0.1 g)III. Inhibiting

Levodopa ( L-DOPA, Dopar ) - a Laevorotatory Isomer of

Adverse effect of Levodopa:Anorexia, VomitingCardiac ArrhythmiasOrthostatic HypotensionAggressive BehaviorSeizuresHallucinations, Confusion, DeliriumDyskinesia – Involuntary

Carbidopa and Benserazide - inhibitors of DOPA decarboxylase – do not

Sinemet (Nakom) : Levodopa 100 mg + Carbidopa 25 mgMadopar :

Bromocriptine, an ergotamine derivative, is a Dopamine Receptor Agonist.The actions are

Selegiline (Deprenil) – MAO-B inhibitorMechanism of Action: This is a selective,

Похожие презентации